An observational study in Amyotrophic Lateral Sclerosis, sponsored by Sykehuset Telemark. Recruiting at 17 sites in Norway. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Sykehuset Telemark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.
After being informed about the study and potential risks, all patients giving written informed consent will be asked to complete a small questionnaire regarding family history and have a blood sample withdrawn. Blood samples, questionnaires, clinical information and signed consent is send to Department of Medical Genetics, Telemark Hospital Trust were the genetic analysis is performed successively throughout the recruitment period. Patients can choose to have their genetic results returned in a diagnostic setting.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Browse Amyotrophic Lateral Sclerosis studies →Sykehuset Telemark is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals diagnosed with ALS that are being followed through the Norwegian health-care system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- not competent to give consent
Individuals diagnosed with ALS that are being followed through the Norwegian health-care system. ALS patients ( probable or definite per El-Escorial criteria)
Other: Observation
Observation of genetic characteristics
Gene frequency
Number of patients with disease causing mutations in high penetrant ALS genes
Time frame: 2020-2030
New ALS genes
Identify new ALS genes in the Norwegian ALS population
Time frame: 2024-2030
Genetic risk factors
Identify genetic risk factors for ALS in Norway.
Time frame: 2022-2030
Started Aug 2019 (actual). Primary completion is estimated for Dec 2030, 136 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Sykehuset Telemark